CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Lonza Group AG Company Snapshot
Lonza Group AG operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other pharmaceutical manufacturers in Europe: UCB Sa of Belgium (2017 sales of 4.53 billion Euro [US$5.18 billion] of which 100% was Biopharmacy), Protek PAO of Russia (258.45 billion Russian Rubles [US$3.91 billion] of which 78% was Distribution), and Stada Arzneimittel AG which is based in Germany (2.31 billion Euro [US$2.64 billion] of which 59% was Generics).

Sales Analysis. During the year ended December of 2017, sales at Lonza Group AG were 5.11 billion Swiss Francs (US$5.09 billion). This is an increase of 23.5% versus 2016, when the company's sales were 4.13 billion Swiss Francs. This was the fourth straight year of sales growth at Lonza Group AG. Sales of Eliminations saw an increase of 15.2% in 2017, from 33.00 million Swiss Francs to 38.00 million Swiss Francs.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Lonza Group AG
  Stock Performance Chart for Lonza Group AG
 
  Stock Data: Recent Stock Performance:
  Current Price (11/2/2018): 323.00
(Figures in Swiss Francs)
1 Week 6.6%   13 Weeks -0.8%  
4 Weeks 4.4%   52 Weeks 20.4%  
 
Lonza Group AG Key Data:
  Ticker: LONN Country: Switzerland
  Exchanges: FRA GVA OTC Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2017 Sales 5,105,000,000
(Year Ending Jan 2018).
Employees: 14,618
  Currency: Swiss Francs Market Cap: 23,907,462,576
  Fiscal Yr Ends: December Shares Outstanding: 74,016,912
  Share Type: Namenaktie Closely Held Shares:
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.